Cytoreductive nephrectomy for metastatic renal cell carcinoma in the era of targeted therapy in the United States: a SEER analysis.
World J Urol., Dec (2012)
Muscle invasive bladder cancer: from diagnosis to survivorship.
Adv Urol., 2012:142135 (2012)
Trends in the use of cytoreductive nephrectomy in the United States.
Clin Genitourin Cancer., Sep;10(3):159-63 (2012)
Trends and variations in utilization of nephron-sparing procedures for stage I kidney cancer in the United States.
World J Urol., May (2012)
The emerging role of circulating tumor cell detection in genitourinary cancer.
J. Urol., Jul;188(1):21-6 (2012)
Successful EUS-guided FNA through a colonic stent array for diagnosis of an extraluminal pelvic malignancy causing colonic obstruction.
Gastrointest. Endosc., Nov;76(5):1070-2 (2012)
Acceptability and preliminary feasibility of an internet/CD-ROM-based education and decision program for early-stage prostate cancer patients: randomized pilot study.
J. Med. Internet Res., 14(1):e6 (2012)
MÃ¼llerian remnant malignancy.
Urology., Mar;79(3):e38-9 (2012)
Pretreatment depressive symptoms and treatment modality predict post-treatment disease-specific quality of life among patients with localized prostate cancer.
Urol. Oncol., Nov;30(6):804-12 (2012)
Integrated safety data from 4 randomized, double-blind, controlled trials of autologous cellular immunotherapy with sipuleucel-T in patients with prostate cancer.
J. Urol., Sep;186(3):877-81 (2011)
Randomized trial of autologous cellular immunotherapy with sipuleucel-T in androgen-dependent prostate cancer.
Clin. Cancer Res., Jul;17(13):4558-67 (2011)
Bladder cancer: current management and opportunities for a personalized approach.
Mt. Sinai J. Med., 77(6):587-96 (2010 Nov-Dec)
Pros and cons of prostate cancer screening: associations with screening knowledge and attitudes among urban African American men.
J Natl Med Assoc., Mar;102(3):174-82 (2010)
Validation of the group-based medical mistrust scale among urban black men.
J Gen Intern Med., Jun;25(6):549-55 (2010)
Impact of hormonal therapy on intermediate risk prostate cancer treated with combination brachytherapy and external beam irradiation.
J. Urol., Feb;183(2):546-50 (2010)
Outcomes for patients with high-grade prostate cancer treated with a combination of brachytherapy, external beam radiotherapy and hormonal therapy.
BJU Int., Dec;104(11):1631-6 (2009)
KLF6-SV1 overexpression accelerates human and mouse prostate cancer progression and metastasis.
J. Clin. Invest., Aug;118(8):2711-21 (2008)
Hormonal implications in the development and treatment of prostate cancer.
Endocrinol. Metab. Clin. North Am., Jun;36(2):421-34 (2007)
Clinical experience with gene therapy for the treatment of prostate cancer.
Rev Urol., 9 Suppl 1:S20-8 (2007)
Community-based free prostate cancer screening program.
Prog Community Health Partnersh., 1(3):215-20 (2007)